Compare Gilead Sciences, Inc. (GILD) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs General Motors Company — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while General Motors Company trades at $82.5 (market cap $71.06B). The key difference: Gilead Sciences, Inc. is far larger — about 2.6× General Motors Company's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and General Motors Company for 83 Days on average.
| GILD | GM | |
|---|---|---|
Market Cap | $182.09B | $71.06B |
Volume | 4,960,247 | 6,269,264 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $90.30 |
52-Week Low | $116.74 | $55.35 |
Typical Hold Time | 111 Days | 83 Days |
Enterprise Value | $205.15B | $174.04B |
Dividend Yield | 2.23% | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
General Motors (GM) trades at $80.99, down 1.24% on the day, amid a broader market downturn and weak Q3 2026 vehicle sales. The stock shows a bearish technical signal, with key support at $80. Fundamentally, GM's revenue dipped to $185.02B in 2025 with a thin net margin of 1.05%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights competitive pressure from Toyota and a 5.5% decline in Q3 U.S. sales, driven by EV softness.
GM faces headwinds from declining market share and high debt levels, but analyst consensus remains bullish with a $102.08 price target, implying significant upside. Investment appeal hinges on execution amid industry shifts, while risks include rising borrowing costs and intense competition. Cash flow stability offers some cushion, but profitability recovery is critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
